Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment outcomes for patients around the world. Health Canada approved BRUKINSA based on data from two single-arm clinical trials, with results indicating it had an overall response rate (ORR) of 84%. Antonella Rizza, Chief Executive Officer at Lymphoma Canada stated that, “The approval of BRUKINSA as a second line therapy is positive news for patients undergoing treatment for mantle cell lymphoma.” This is the second time BRUKINSA has been approved in Canada – in March 2021 the treatment was also approved for patients with Waldenström’s macroglobulinemia (WM).
Read more here.